Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumor 1Advanced Solid Tumors 1

Interventions

Injections 6Fluorodeoxyglucose F18 4Cyclophosphamide 4Bevacizumab 4toripalimab 3fludarabine 2Specimen Handling 2Nivolumab 2zimberelimab 1tumor-cells apoptosis factor, human 1trametinib 1tislelizumab 1temsirolimus 1spartalizumab 1pembrolizumab 1pazopanib 1palbociclib 1olaparib 1lenvatinib 1etoposide phosphate 1enzalutamide 1envafolimab 1donafenib 1disitamab vedotin 1dabrafenib 1cemiplimab 1avelumab 1atezolizumab 1anlotinib 1WW Domain-Containing Oxidoreductase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Solid Tumor × WW Domain-Containing Oxidoreductase × Clear all
NCT07229638 2026-03-20

A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1/2 Recruiting
70 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡